Direct and selective inhibition of MDM4 for treatment of cancer
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
Nov 12, 2024
Grant Date -
Dec 17, 2020
app pub date -
Aug 21, 2020
filing date -
Aug 21, 2020
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present application relates to the field of cancer, particularly that of cancers with high MDM4 protein levels (such as melanoma, breast, colon or lung cancers, glioblastoma, retinoblastoma, etc.). It is shown herein that direct and selective inhibition of MDM4, e.g., by antisense RNA, leads to growth inhibition of cancer cells and sensitization to chemo or targeted therapies. Also provided are simple ways of determining which patients are most amenable for such treatment by comparing specific transcript levels.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully